Clinical trials: T1D
Caffeine and Carbohydrate, Carbohydrate Only
Caffeine Ingestion to Counter the Exercise-mediated Fall in Glycaemia in Type 1 Diabetes
This project will aim to investigate the clinical efficacy and metabolic effects of a pre-exercise dose of caffeine with a low (10g) dose of carbohydrate (CAF+lowCHO) without modification of insulin degludec on exercise…
- Conditions
- Caffeine and Carbohydrate, Carbohydrate Only, Placebo
- Trial name
- DE-CAF (NCT04671043)
- Testing
- Caffeine and glucose, Glucose alone
- Where
- Switzerland
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Type 1 Diabetes
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2
In previous studies, investigators have studied if a pre-meal insulin bolus based on estimated carbohydrate meal size would alleviate the burden of carbohydrate counting without a significant degradation in postprandial glucose…
- Trial name
- NCT02798250
- Testing
- Dual-hormone closed-loop, Insulin, Glucagon
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Diabetes Mellitus Type 1
Effects of XOMA 052 on Insulin Production in Type 1 Diabetes
To assess the effects of treatment with XOMA 052 on beta-cell function and insulin production in subjects with well-controlled Type 1 diabetes. The safety, tolerability, and pharmacokinetics (PK) of XOMA 052 will also be assessed.
- Trial name
- LATE STAGE (NCT01788033)
- Testing
- XOMA 052
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
Diabetes Mellitus, Type 1
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
This open-label study aims to evaluate the impact of BI 10773 treatment on glomerular filtration rate under controlled conditions of euglycaemia and hyperglycaemia in subjects with type 1 diabetes mellitus with or without renal…
- Trial name
- NCT01392560
- Testing
- BI 10773
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
An 8-Day Initiation of Advanced Hybrid Closed Loop System In Children and Adolescents
One of the available Hybrid closed loop system is MiniMed 670G (Medtronic Diabetes, Northridge, CA, USA), which is indicated for children above 7 years old, adolescents and adults with Type 1 Diabetes.
- Trial name
- NCT04509362
- Testing
- Advanced Hybrid Closed Loop System
- Where
- Qatar
- Volunteers
- 34 people
- Sponsor
- Sidra Medicine
Type 1 Diabetes Mellitus, Pregnancy
Orchestra Pregnancy Observational Study in Poland
The aim of this project is to document the use of insulin pump therapy (CSII), including sensor augmented pump therapy (SAP), before, during and after pregnancy in women with type 1 Diabetes Mellitus benefiting from the Orchestra…
- Trial name
- NCT01779141
- Where
- 24 sites in Poland
- Volunteers
- 481 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population
The study aims to assess foot complications among patients with diabetes in Canada, using patient data collected during diabetes foot assessments performed by the LMC Chiropody Team between February 27, 2018 and April 17, 2019.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Foot Deformities, Onychauxis
- Trial name
- PEDAL (NCT04327622)
- Where
- Canada
- Volunteers
- 5,084 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Type 1 Diabetes Mellitus
Islet Cell Transplant for Type 1 Diabetes
City of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on islet cell transplantation, an experimental procedure being evaluated as a treatment for patients with type 1 diabetes.
- Trial name
- TCD (NCT01909245)
- Testing
- Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Contact Dermatitis, Type 1 Diabetes Mellitus
Exploring Skin Barrier Function, Recurrence of Diabetes Device-Related Contact Dermatitis, and Evaluation of Hydrocolloid and Silicone-Based Patches for Its Prevention in Children and Adolescents With Type 1 Diabetes
The goal of this clinical trial is to ensure that contact dermatitis does not prevent any person with diabetes from accessing optimal diabetes treatment.
- Trial name
- StenoAD1 (NCT07767461)
- Testing
- hydrocolloid patch as patch used in the Sandwich method, Silicone-based patch as patch used in the Sandwitch method
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Thailand.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00805922)
- Testing
- No treatment given
- Where
- Thailand
- Volunteers
- 2,342 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Type 2 Diabetes (T2DM)
CGM Use in Non-insulin Patients With DM2
The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications…
- Conditions
- Diabetes, Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Trial name
- CGM-DWI (NCT07128342)
- Testing
- CGM Group, FSBG group
- Volunteers
- 100 people
- Sponsor
- Milwaukee VA Medical Center
Diabetes Mellitus, Type 1
CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections
Breif summary A keystone in preventing diabetic complications in patients with type 1 diabetes is good glycaemic control. Frequent self-measurements of blood glucose (SMBG) levels has been an essential part of insulin dosing…
- Trial name
- NCT02092051
- Testing
- Continuous glucose monitoring with DexCom G4 platina
- Where
- 15 sites in Sweden
- Volunteers
- 161 people
- Sponsor
- Vastra Gotaland Region
Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
- Trial name
- TN05 (NCT00279305)
- Testing
- Anti-CD20 (rituximab)
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 87 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Type 1 Diabetes Mellitus
A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes
The purpose of this study is to see if a patient's ability (and/ or parent) to read, write, and do basic math problems affects blood sugar control in children with type 1 diabetes mellitus.
- Conditions
- Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- NCT00717223
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Baylor College of Medicine
Type 1 Diabetes, Type 2 Diabetes
COVID-19 Glycemic Control Study
Diabetes mellitus is a chronic disease characterized by the inability of the body to maintain normoglycemia. Treatment of diabetes relies mostly on diabetes self-management, requiring a large investment of time and energy on a…
- Trial name
- NCT05977205
- Testing
- No interventions, observational study
- Where
- Netherlands
- Volunteers
- 492 people
- Sponsor
- Leiden University Medical Center
Type 1 Diabetes Mellitus
Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement
The aim of this pilot study is to generate preliminary data of (i) Fiasp-plus-Pramlintide closed-loop system with a simple meal announcement, compared to (ii) Fiasp-alone closed-loop system with full carbohydrate counting, in…
- Trial name
- NCT03993366
- Testing
- Fiasp+Pramlintide Closed-Loop System, Fiasp Closed-Loop System
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McGill University
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™
This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data in diabetic patients with acute hyperglycemia using NovoRapid™ FlexPen™ as per normal clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00675220
- Testing
- insulin aspart
- Where
- Philippines
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Hypoglycemia
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
Type 1 diabetes (T1D) results from destruction of insulin producing beta cells by the body's own immune system (autoimmunity) causing an individual to lose the ability to make enough insulin to control their blood sugar levels…
- Trial name
- MUGGLE (NCT05616273)
- Testing
- Mixed Meal Tolerance Test (MMTT), Arginine Stimulation Test (AST), Home Finger Prick Sample
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Exeter
Diabetes Mellitus Type 1
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
- Trial name
- NCT01334151
- Testing
- Insulin LISPRO, recombinant human insulin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Biodel